TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8006647

Group type: EXPERIMENTAL
Intervention: Sodium valproate (Epilim EC enteric coated 200 mg tablets twice daily)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Carbamazepine (100 mg twice daily increasing to 200 mg twice daily in week 2)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sodium valproate and carbamazepine
Number of subjects: 300
Study: 29982608

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNPs in ACE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNP rs4318 in ACE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27451968

Group type: EXPERIMENTAL
Intervention: State mandatory reporting laws for healthcare-associated infections (HAIs)
Number of subjects: 244

Group type: COMPARATOR
Intervention: No specific intervention mentioned (control group)
Number of subjects: 244
Study: 26457003

Group type: EXPERIMENTAL
Intervention: Blood NH3 levels in male prisoners
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Blood H2S levels in male prisoners
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Aggressive behavior assessment, Self‐Rating Depression Scale (SDS), State‐Trait Anxiety Inventory (STAI)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 101
Study: 23204544

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Gadoteridol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Gadoteridol with leakage correction
Number of subjects: 19
Study: 19160404

Group type: EXPERIMENTAL
Intervention: Topical amphotericin B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17449993

Group type: EXPERIMENTAL
Intervention: Irritable Bowel Syndrome (IBS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fibromyalgia plus Irritable Bowel Syndrome (FM+IBS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hand immersion
Number of subjects: 37
Study: 14970005

Group type: EXPERIMENTAL
Intervention: BCAA mixture intake (0, 20, 30, 50, 60, 70, 90, 110, and 130 mg.kg(‐1).day(‐1))
Number of subjects: 5
Study: 11961245

Group type: EXPERIMENTAL
Intervention: Amicus DN
Number of subjects: 12

Group type: COMPARATOR
Intervention: Spectra LRS
Number of subjects: 12

Group type: COMPARATOR
Intervention: MCS+
Number of subjects: 12
Study: 9854277

Group type: EXPERIMENTAL
Intervention: Supervised fitness training under bright light (2500-4000 lx) 2-3 times weekly for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supervised fitness training under ordinary light (400-600 lx) 2-3 times weekly for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supervised relaxation training once a week for 8 weeks (active placebo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Supervised fitness training combined with bright light
Number of subjects: 120
Study: 8582955

Group type: EXPERIMENTAL
Intervention: Cabergoline 1.0 mg oral administration for inhibition of puerperal lactation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabergoline 1.0 mg (0.25 mg twice daily for 2 days) for suppression of established lactation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabergoline 1-2 mg weekly doses (twice weekly schedule) for hyperprolactinaemic amenorrhoea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 0
Study: 2121406

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g with five-minute tourniquet inflation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g with two-minute tourniquet inflation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g with one-minute tourniquet inflation
Number of subjects: 24
Study: 374706

Group type: EXPERIMENTAL
Intervention: Alexidine mouthrinse (0.035%)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 180
Study: 31122062

Group type: EXPERIMENTAL
Intervention: TVBGSA model
Number of subjects: 134

Group type: COMPARATOR
Intervention: BGSA method
Number of subjects: 134
Study: 28668719

Group type: EXPERIMENTAL
Intervention: Rapid acting insulin analog (RAIA)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Nurse perceptions of RAIA dosing
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Nurse perceptions of electronic dosing calculator and patient reminder
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Hypoglycemia incidence
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Timeliness measures and mean CBG
Number of subjects: 451
Study: 25387903

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 164
Study: 23972437

Group type: EXPERIMENTAL
Intervention: Externally supported PTFE graft
Number of subjects: 334

Group type: COMPARATOR
Intervention: Ordinary PTFE graft
Number of subjects: 334
Study: 21589921

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 20
Study: 19167693

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 150 mg
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 567
Study: 17233679

Group type: EXPERIMENTAL
Intervention: 10 weeks of supervised exercise consisting of high-intensity progressive resistance training (80% of 1RM) 3 days per week, moderate-intensity aerobic training (RPE 11 to 14/20) 2 days per week, and progressive balance training 1 day per week.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 10 weeks of supervised exercise
Number of subjects: 38
Study: 14978178

Group type: EXPERIMENTAL
Intervention: Intensive intervention (feedback, workshops, educational materials, technical assistance, continued monitoring)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Feedback alone (control)
Number of subjects: 42
Study: 12238431

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 10
Study: 9638033

Group type: EXPERIMENTAL
Intervention: Caffeine (4.5 mg caffeine/kg fat-free mass)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no caffeine)
Number of subjects: 16
Study: 8206809

Group type: EXPERIMENTAL
Intervention: Sulpiride 150 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sulpiride 300 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2536517

Group type: EXPERIMENTAL
Intervention: Fish-oil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Olive-oil
Number of subjects: 32
Study: 4885615

Group type: EXPERIMENTAL
Intervention: Dipyridamole (400 mg daily for 14 months, then 800 mg daily for 11 months)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 31996130

Group type: EXPERIMENTAL
Intervention: Exercise group (performed masseter muscle massage and stretching of jaw and neck joints before anesthetic induction)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study: 30365461

Group type: EXPERIMENTAL
Intervention: Laser-assisted corticosteroid delivery (topical triamcinolone acetonide 20 mg/mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laser-assisted 5-fluorouracil delivery (topical 5-fluorouracil 50 mg/mL)
Number of subjects: 20
Study: 26269215

Group type: EXPERIMENTAL
Intervention: T-tube (TT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 21
Study: 25304269

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Metformin (Met)
Number of subjects: 110
Study: 24131091

Group type: EXPERIMENTAL
Intervention: Pinpoint irradiation technique by CO₂ LASER (14 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: TCA CROSS (14 patients)
Number of subjects: 32
Study: 23244536

Group type: EXPERIMENTAL
Intervention: 1.5 g/d c9, t11 CLA for 16 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 3.0 g/d c9, t11 CLA for 16 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 31
Study: 19032576

Group type: EXPERIMENTAL
Intervention: ondansetron 0.5 mg/d
Number of subjects: 15

Group type: COMPARATOR
Intervention: sertraline 200 mg/d
Number of subjects: 15
Study: 17522585

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) 70 microg/kg administered intravenously
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 23
Study: 15866013

Group type: EXPERIMENTAL
Intervention: Sterillium Virugard (95% ethanol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sterillium Rub (80% ethanol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desderman N (75.1% ethanol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 70% ethanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 70% propan-1-ol
Number of subjects: 0
Study: 12528763

Group type: EXPERIMENTAL
Intervention: Twelve weeks of treadmill exercise training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 32
Study: 9606434

Group type: EXPERIMENTAL
Intervention: Paranoid schizophrenia
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Residual schizophrenia
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Disorganized schizophrenia
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 84
Study: 7705381

Group type: EXPERIMENTAL
Intervention: Tissue-plasminogen activator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2649461

Group type: EXPERIMENTAL
Intervention: Topical infusion of metronidazole solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment without metronidazole
Number of subjects: 0
Study: 360759

Group type: EXPERIMENTAL
Intervention: Ro 8-4650
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31952545

Group type: EXPERIMENTAL
Intervention: VIDE induction and VAI/VAC/BuMel consolidation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VDC/IE induction and IE/VC/VAI/BuMel consolidation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of zoledronic acid to consolidation chemotherapy
Number of subjects: 0
Study: 28322667

Group type: EXPERIMENTAL
Intervention: PATH Program (8-week intervention)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait-listed control group (revised version of the program)
Number of subjects: 20
Study: 26925641

Group type: EXPERIMENTAL
Intervention: Spiritual care training package (seven group training sessions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 24559811

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1g of ginger
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2g of ginger
Number of subjects: 45
Study: 22517413

Group type: EXPERIMENTAL
Intervention: Lersivirine with lopinavir/ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lersivirine with darunavir/ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lersivirine with atazanavir/ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lersivirine with atazanavir (without ritonavir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atazanavir with/without ritonavir
Number of subjects: 0
Study: 20439056

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (average 10 sessions)
Number of subjects: 9990

Group type: EXPERIMENTAL
Intervention: Internists
Number of subjects: 9990

Group type: EXPERIMENTAL
Intervention: Orthopedists
Number of subjects: 9990

Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 9990
Study: 18605178

Group type: EXPERIMENTAL
Intervention: Violent movie previews
Number of subjects: 159

Group type: COMPARATOR
Intervention: Nonviolent movie previews
Number of subjects: 159
Study: 15824361

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 1,300 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12066083

Group type: EXPERIMENTAL
Intervention: Subcutaneous stitch closure
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Subcutaneous drain placement
Number of subjects: 964

Group type: COMPARATOR
Intervention: No closure
Number of subjects: 964
Study: 10910540

Group type: EXPERIMENTAL
Intervention: Regular insulin (RI) infusion (n = 20); ratio of infusion glucose to regular insulin was 10‐15 gm glucose to 1 unit RI, glucose infusion rate maintained at least 6 mg/Kg/min.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kayexalate resin enema (n = 20); dose of Kayexalate was 1 gm/Kg body weight given rectally every four hours.
Number of subjects: 40
Study: 8584194

Group type: EXPERIMENTAL
Intervention: Intrapleural analgesia with bupivacaine boluses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caudal epidural analgesia with bupivacaine and morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endovenous analgesia with morphine boluses
Number of subjects: 0
Study: 1773242

Group type: EXPERIMENTAL
Intervention: Nutritional Management (NM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Stress Management (SM)
Number of subjects: 55
Study: 6295422

Group type: EXPERIMENTAL
Intervention: sequential hemi-body irradiation (HBI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 3-drug cyclic chemotherapy (CC)
Number of subjects: 64
Study: 31272528

Group type: EXPERIMENTAL
Intervention: 10 mg memantine tablet formulation A
Number of subjects: 19

Group type: COMPARATOR
Intervention: 10 mg memantine tablet formulation B
Number of subjects: 19
Study: 29453468

Group type: EXPERIMENTAL
Intervention: Ondansetron 4mg (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25mg/kg (Group 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tramadol 0.5mg/kg (Group 4)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (Group 1)
Number of subjects: 120
Study: 26066703

Group type: EXPERIMENTAL
Intervention: Siluron2000 silicone oil
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: F4H5 (perfluorobutylpentane)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Siluron5000 silicone oil
Number of subjects: 72
Study: 25058083

Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 156

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 156
Study: 22984401

Group type: EXPERIMENTAL
Intervention: Novel HIV confirmatory testing algorithm
Number of subjects: 9385
Study: 18547343

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 30
Study: 17575222

Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation plus radiotherapy (STAD+RT)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation plus radiotherapy (LTAD+RT)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Bcl-2
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Bax
Number of subjects: 502
Study: 15189492

Group type: EXPERIMENTAL
Intervention: NPH insulin (mean dose 0.33 +/- 0.15; range 0.09-0.66 units/kg/d) administered twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Matched observation group (natural history studies)
Number of subjects: 26
Study: 11606504

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (Is-MN)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 9608152

Group type: EXPERIMENTAL
Intervention: Nonverbal LD group (VIQ >= 95, PIQ at least 25 points lower than VIQ)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Verbal LD group (PIQ >= 95, VIQ at least 25 points lower than PIQ)
Number of subjects: 89
Study: 8083823

Group type: EXPERIMENTAL
Intervention: Concomitant medications (average of 7.1 drugs per month for AIDS patients)
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Concomitant medications (average of 3.1 drugs per month for ARC patients)
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Concomitant medications (average of 2.7 drugs per month for asymptomatic patients)
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Acyclovir usage
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Drug classes used
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Prescription vs. over-the-counter drugs
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Demographic subgroup analysis
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Antivirals and vitamins consumption
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Analgesics or antipyretics consumption
Number of subjects: 2801
Study: 3060379

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 20

Group type: COMPARATOR
Intervention: GnRH agonists
Number of subjects: 20
Study: 30875386

Group type: EXPERIMENTAL
Intervention: Initial exposure to a prosocial donation decision
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Contribution-to-others beliefs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Autonomy and self-development well-being beliefs interaction
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control groups (totally self-focused and no first-exposure)
Number of subjects: 200
Study: 28985268

Group type: EXPERIMENTAL
Intervention: Intensive treatment (targeting SBP ≤ 120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment (targeting SBP ≤ 140 mm Hg)
Number of subjects: 9361
Study: 25527747

Group type: EXPERIMENTAL
Intervention: Natural almonds (NAs)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Roasted almonds (RAs)
Number of subjects: 17
Study: 23706890

Group type: EXPERIMENTAL
Intervention: 8-week yoga intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Attention-control activity
Number of subjects: 27
Study: 16982941

Group type: EXPERIMENTAL
Intervention: Primary training group (exercise and respiratory training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 14572944

Group type: EXPERIMENTAL
Intervention: Intervention group (practitioners who read and discussed the feedback report)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study: 10226959

Group type: EXPERIMENTAL
Intervention: Self-training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Physiotherapist-supervised rehabilitation
Number of subjects: 43
Study: 8723308

Group type: EXPERIMENTAL
Intervention: Oral paroxetine
Number of subjects: 0
Study: 1806624

Group type: EXPERIMENTAL
Intervention: mianserin (60‐90 mg/day)
Number of subjects: 317
Study: 6308685

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 25 mg t.i.d. alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 25 mg t.i.d. with hydrochlorothiazide (HCTZ) 50 mg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril (ENA) 5 or 10 mg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril (ENA) with hydrochlorothiazide (HCTZ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31988226

Group type: EXPERIMENTAL
Intervention: Referral to a commercial weight management programme plus stop smoking support (treatment group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Stop smoking support alone (control group)
Number of subjects: 76
Study: 31121138

Group type: EXPERIMENTAL
Intervention: Indwelling Foley catheter
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self‐catheterization
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as those who did not pass the voiding trial)
Number of subjects: 150
Study: 28403408

Group type: EXPERIMENTAL
Intervention: Lidocaine (i.v.‐bolus injection of 1.5 mg kg ‐1 at induction of anaesthesia, followed by an infusion of 1.5 mg kg ‐1 h ‐1 until six h after arrival at the post‐anaesthesia care unit)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (equal volumes of saline)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25171056

Group type: EXPERIMENTAL
Intervention: 5,6-DMB supplement (1.5 g daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No supplement (Control)
Number of subjects: 8
Study: 23535096

Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) 50-U/kg intravenous dose
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) repeated treatment
Number of subjects: 62
Study: 21908890

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 67

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (CABG)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both PCI and CABG
Number of subjects: 67
Study: 18829443

Group type: EXPERIMENTAL
Intervention: Korean hand acupuncture therapy (HAT), 10 sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand moxibustion therapy (HMT), 10 sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16505133

Group type: EXPERIMENTAL
Intervention: 1.0 to 1.5 mg risperidone per day
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473